The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy

Su-hu Liu,1,2 Anna E. Marneth,3 Gabriela Alexe,4 Sarah R. Walker,1,2 Helen I. Gandler,1 Darwin Q. Ye,1 Katherine Labella,1 Radhika Mathur,1 Patricia A. Toniolo,1 Michelle Tillgren,5 Prafulla C. Gokhale,5 David Barbie,1,2 Ann Mullally,1,3,6 Kimberly Stegmaier,4 and David A. Frank1,2

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; 3Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 4Department of Pediatric Oncology and 5Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, and 6Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, MA

Key Points

• The noncanonical IkB kinase IKBKE is commonly upregulated in AML and promotes MYC expression through phosphorylation of YB-1.
• Targeting IKBKE genetically or through drugs such as momelotinib provides a therapeutic benefit in models of AML.

To identify novel therapeutic targets in acute myeloid leukemia (AML), we examined kinase expression patterns in primary AML samples. We found that the serine/threonine kinase IKBKE, a noncanonical IkB kinase, is expressed at higher levels in myeloid leukemia cells compared with normal hematopoietic cells. Inhibiting IKBKE, or its close homolog TANK-binding kinase 1 (TBK1), by either short hairpin RNA knockdown or pharmacological compounds, induces apoptosis and reduces the viability of AML cells. Using gene expression profiling and gene set enrichment analysis, we found that IKBKE/TBK1-sensitive AML cells typically possess an MYC oncogenic signature. Consistent with this finding, the MYC oncoprotein was significantly downregulated upon IKBKE/TBK1 inhibition. Using proteomic analysis, we found that the oncogenic gene regulator YB-1 was activated by IKBKE/TBK1 through phosphorylation, and that YB-1 binds to the MYC promoter to enhance MYC gene transcription. Momelotinib (CYT387), a pharmacological inhibitor of IKBKE/TBK1, inhibits MYC expression, reduces viability and clonogenicity of primary AML cells, and demonstrates efficacy in a murine model of AML. Together, these data identify IKBKE/TBK1 as a promising therapeutic target in AML.

Introduction

Despite advances in our molecular understanding of the pathogenesis of acute myeloid leukemia (AML), the core of standard therapy for this disease remains nonspecific cytotoxic chemotherapy. Consequently, treatment is associated with high morbidity, and >10 000 patients die of AML each year in the United States. Identifying novel therapeutic targets and developing corresponding molecular therapies is an urgent need for the treatment of this disease.

IκB kinase ε (IKBKE) and its close homolog TBK1 (TANK-binding kinase 1) belong to the noncanonical IκB kinase family and participate in the regulation of the immune response.1 These 2 enzymes functionally compensate each other. However, although TBK1 is ubiquitously expressed, expression of IKBKE is restricted to particular tissue compartments, with the highest levels detected in lymphoid tissue and the pancreas.2 Recently, a role for IKBKE/TBK1 in tumor pathogenesis has been recognized. Increased expression of IKBKE has been found in multiple types of cancer, including breast,3 lung,4 ovarian cancer,5 and glioma.6 IKBKE was first recognized as an oncogene in breast cancer by integrative genomic approaches. IKBKE was found to be amplified in 30% of cases and was able to substitute for AKT in transforming mammary epithelial cells.3 In addition, interleukin-1 inflammatory signals are correlated with increased IKBKE expression in triple-negative breast cancers even in the absence of genomic amplification.7 In lung
activation of STAT3 was found to be correlated with IKBKE upregulation. Most evidence ties the oncogenic effects of IKBKE/TBK1 to promoting NF-κB pathway activation. As a serine/threonine kinase, several substrates have been identified to be phosphorylated by IKBKE or TBK1, including CYLD, FOXO3a, TRAF2, AKT, ERα, PLK1, and IRF3.

Given the role that many of these pathways play in the pathogenesis of AML, we characterized the role of IKBKE/TBK1 in AML cell survival and evaluated the potential of pharmacological inhibitors of these kinases for the treatment of AML.

**Materials and methods**

**Analysis of gene expression data from primary AML samples**

The expression of IKBKE (probes 204549_at and 214398_s_at) and TBK1 (probe 218520_at) was studied in a publicly available microarray dataset containing data on 525 AML samples, 14 CD34+ samples, and 5 normal bone marrow control samples. The Mann-Whitney U test (Graphpad Prism 7) was performed to study whether IKBKE and TBK1 median expression were significantly different between sample groups.
Figure 2. AML cells display differential sensitivity to inhibition of IKBKE and TBK1. (A) AML cell lines were infected with lentiviral vectors containing either shRNA targeting luciferase (shLUC) as a negative control, or the indicated IKBKE or TBK1 shRNA. Following selection in puromycin for 3 days, IKBKE and TBK1 protein levels in
To study whether high **IKBKE** and **TBK1** expression were prognostic factors, AML patients were subdivided into groups of high- and low-intermediate-expression levels. The overall survival was displayed in Kaplan-Meier plots (Graphpad 7). A 2-tailed log-rank method (SPSS Statistics version 24) was used to test whether survival of patient groups with high (highest 10%) vs low/intermediate (lowest 90%) expression was statistically different. The Cox proportional hazard model was applied for multivariate analysis to study whether high **IKBKE** expression was an independent prognostic factor (SPSS Statistics version 24). Factors included in the multivariate model were age, white blood cell count, favorable karyotypes (t(8;21), INV(16), and t(15;17)), **CEBPA** double mutations, **FLT3-ITD,** and **NPM1** mutations.

**Cells**

The AML cell lines were obtained from James Griffin (Dana-Farber Cancer Institute, Boston, MA) and cultured in RPMI 1640 media supplemented with 10% (for MOLM13, MOLM14, HL60, 31P, NOMO1, and MV411) or 20% fetal bovine serum (FBS; for KASUMI-1 and KG-1a). SKNO1, OCI-AML5, and AML193 were cultured in RPMI 1640 media supplemented with 10% FBS and 5 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF).

Bone marrow mononuclear cells from patients with untreated AML and from healthy donors were obtained through a Dana-Farber Cancer Institute Institutional Review Board–approved protocol for which subjects gave written informed consent in accordance with the Declaration of Helsinki. For liquid culture studies, cells were maintained in RPMI 1640 media supplemented with 10% FBS, L-glutamine, sodium pyruvate, essential amino acids and vitamins, β-mercaptoethanol, penicillin, and streptomycin.

**Reagents**

Momelotinib (CYT387) was obtained from Gilead Sciences (Foster City, CA), and MRT67307 and Ruxolitinib were obtained from Shanghai Haoyuan Chemexpress Co. Ltd. BX-795 was obtained from Selleck Chemicals; BAY-11-7082 was obtained from Calbiochem, and LY294002 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). All compounds were solubilized in dimethyl sulfoxide (DMSO), which was also used as a vehicle control for all drug treatments. The S102D mutant of YB-1 was kindly provided by Sandra Dunn, University of British Columbia, Vancouver, Canada.

**Immunoblots and chromatin immunoprecipitation (ChIP)**

Immunoblots and ChIP were performed using the following antibodies: Anti-TBK1 (#3013), Ser102 YB1 (#2900), S473 pAKT (#9272), AKT (#9271), KRAS.KIDNEY_UP.V1_UP 1.461089 0.069305, MYC_UP.V1_UP 1.461089 0.069305, LET2_UP.V1_DN 1.447226 0.070641, KRAS.KIDNEY_UP.V1_UP 1.462204 0.079712, CAHOY_ASTROCYTIC 1.556317 0.084935

<table>
<thead>
<tr>
<th>Gene set</th>
<th>NES</th>
<th>FDR q value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALK_DN.V1_UP</td>
<td>1.530436</td>
<td>0.05621</td>
</tr>
<tr>
<td>PRC2_SUZ12.UP.V1.DN</td>
<td>1.546459</td>
<td>0.063283</td>
</tr>
<tr>
<td>PTEK.DN.V1.DN</td>
<td>1.489504</td>
<td>0.069137</td>
</tr>
<tr>
<td>MYC_UP.V1_UP</td>
<td>1.461089</td>
<td>0.069305</td>
</tr>
<tr>
<td>LET2_UP.V1_DN</td>
<td>1.447226</td>
<td>0.070641</td>
</tr>
<tr>
<td>KRAS.KIDNEY.UP.V1.UP</td>
<td>1.462204</td>
<td>0.079712</td>
</tr>
<tr>
<td>CAHOY_ASTROCYTIC</td>
<td>1.556317</td>
<td>0.084935</td>
</tr>
</tbody>
</table>

FDR, false discovery rate; NES, normalized enrichment score.

**Table 1. Gene sets enriched in IKBKE/TBK1-knockdown–sensitive AML cells**

<table>
<thead>
<tr>
<th>Gene set name</th>
<th>P</th>
<th>FDR q value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL15_UP.V1.UP</td>
<td>3.89E-14</td>
<td>3.20E-12</td>
</tr>
<tr>
<td>HOX9_DN.V1.DN</td>
<td>4.74E-14</td>
<td>3.20E-12</td>
</tr>
<tr>
<td>MOTR_UP.N4.V1_UP</td>
<td>5.07E-14</td>
<td>3.20E-12</td>
</tr>
<tr>
<td>MOTR_UP.V1_UP</td>
<td>2.34E-13</td>
<td>1.10E-11</td>
</tr>
<tr>
<td>IL2_UP.V1.UP</td>
<td>9.96E-13</td>
<td>3.76E-11</td>
</tr>
<tr>
<td>MYC_UP.V1.UP</td>
<td>7.09E-09</td>
<td>2.23E-07</td>
</tr>
<tr>
<td>MEL18.DN.V1_UP</td>
<td>2.96E-07</td>
<td>7.27E-06</td>
</tr>
<tr>
<td>STK33.DN</td>
<td>3.08E-07</td>
<td>7.27E-06</td>
</tr>
<tr>
<td>BM1_DN.V1.UP</td>
<td>3.92E-07</td>
<td>8.23E-06</td>
</tr>
<tr>
<td>RPS4.DN.V1.DN</td>
<td>1.97E-06</td>
<td>3.72E-05</td>
</tr>
</tbody>
</table>

**Table 2. Gene sets downregulated following momelotinib treatment**

To study whether high **IKBKE** and **TBK1** expression were prognostic factors, AML patients were subdivided into groups of high- and low-intermediate-expression levels. The overall survival was displayed in Kaplan-Meier plots (Graphpad 7). A 2-tailed log-rank method (SPSS Statistics version 24) was used to test whether survival of patient groups with high (highest 10%) vs low/intermediate (lowest 90%) expression was statistically different. The Cox proportional hazard model was applied for multivariate analysis to study whether high **IKBKE** expression was an independent prognostic factor (SPSS Statistics version 24). Factors included in the multivariate model were age, white blood cell count, favorable karyotypes (t(8;21), INV(16), and t(15;17)), **CEBPA** double mutations, **FLT3-ITD,** and **NPM1** mutations.

**Immunoblots and chromatin immunoprecipitation (ChIP)**

Immunoblots and ChIP were performed using the following antibodies: Anti-TBK1 (#3013), Ser102 YB1 (#2900), S473 pAKT (#9271), AKT (#9272), β-Actin (#4970) (Cell Signaling Technologies); YB1 (#17250002; Novus Biologicals); IKBKE (#14907; Sigma); and, MYC (sc-764; Santa Cruz Biotechnology).

ChIP was performed as described. Briefly, leukemia cells were formaldehyde fixed and sonicated, and lysates were immunoprecipitated with anti-YB1 antibody. Quantitative polymerase chain reaction was performed in triplicate on ChIP product or input using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and region-specific primers for the MYC promoter (forward 5’-TACTAGGCGCGTCATGGTATAC-3’, reverse 5’-AAGGGTGGGG-AAGGAGACTCAG-3’). Values were normalized to input and expressed as mean fold change relative to a negative control DNA binding site.

**Colon-forming unit assays**

Normal bone marrow CD34+ cells were isolated using the CD34 MicroBead Kit Ultrapure and LS columns according to manufacturer’s instructions (MACS Miltenyi Biotec). Donor CD34+ cells or primary AML samples (>90% blasts) were cultured in StemSpan Serum-Free Expansion Medium supplemented with 100 ng/μL
Figure 3. IKBKE/TBK1 inhibition modulates MYC signaling pathway. (A) GSEA of shIKBKE/TBK1-sensitive vs -resistant AML cell lines. Gene set databases used are c6 oncogenic signature and c1 hallmarks. (B-D) MOLM14 or OCIAML5 cells were treated with momelotinib (CYT; 2.5 μM), MRT (2.5 μM), BX795 (2.5 μM), or ruxolitinib (10 μM) for 6 hours, after which RNA or protein was isolated. 18S RNA was used as an internal control for RNA quantification. For OCIAML5, cells were cultured without...
concentrations of momelotinib (CYT387) in a humidified incubator at 37°C with 5% CO2. After overnight incubation, cells were harvested, and 1000 to 1500 CD34+ or 8500 to 130,000 AML cells were seeded in triplicate into MethoCult (H4435; StemCell Technologies) supplemented with 1% penicillin-streptomycin-glutamine, and DMSO or momelotinib for colony-forming unit (CFU-GEMM) assays. Colony and cell numbers were assessed another 11 to 14 days after lentiviral vector infection and cellular viability 5 days after lentiviral infection using CellTiter-Glo.

**Reverse phase protein array (RPPA)**

RPPA was carried out by the RPPA core facility at the MD Anderson Cancer Center, as described. Briefly, proteins were collected from MOLM14 or OCI-AML5 cells after momelotinib treatment or shRNA knockdown of IKBKE/TBK1. Proteomic analysis of protein expression and phosphorylation states in these samples were evaluated with 218 validated antibodies.

**Gene set enrichment analysis (GSEA)**

GSEA was performed using GSEA software to determine whether a defined set of genes shows statistically significant difference between given phenotypes. The defined gene set databases used were the c6 oncogenic signature and c1 hallmarks. Gene set investigation was performed by computing overlaps between the input gene set (the gene set down regulated by momelotinib treatment) and gene set collections in Molecular Signatures Database v6.1 (http://software.broadinstitute.org/gsea/msigdb/).

**Mouse studies**

Female NSG mice were injected with 1 × 10⁶ MOLM-14-Luc cells in 250 μL phosphate-buffered saline via IV injection. Mice were imaged on days 4 and 8 after cell implantation and randomized into vehicle or treatment groups (n = 8 per group) on day 8. Animals were then treated by either oral gavage with vehicle (10% NMP: 90% [0.5% methylcellulose + 0.4% Tween 80]) or momelotinib at the indicated doses. Bioluminescence imaging was performed once or twice a week for 4 weeks to monitor disease progression, and body weights were measured twice weekly. Spleens were collected 2 hours after the last treatment dose on day 28, photographed, and then flash frozen for further analysis.

**Results**

**IKBKE is highly expressed in AML cells**

To identify novel targets for the therapy of AML, we examined kinase expression patterns in publicly available compendia of gene expression data sets. We found that the serine/threonine kinase IKBKE, a noncanonical IkB kinase, is especially highly expressed in hematological malignancies compared with other tumor types (Figure 1A). Although IKBKE transcripts are also present in normal hematopoietic cells, IKBKE is expressed at higher levels in myeloid leukemia cells compared with normal hematopoietic and CD34+ cells (Figure 1B-C; supplemental Figure 1A). Although high expression is found in most genetically defined AML subtypes, the
Figure 4. IKBKE/TBK1 modulates MYC through phosphorylation of YB-1. (A) Phosphorylated YB-1 is decreased in AML cells following either treatment with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1, as determined by RPPA. MOLM14 or OCIAML5 cells were treated with momelotinib (CYT; 2.5 μM) for 2 or 6 hours before whole cell extracts were prepared for RPPA analysis. For shRNA experiments, cells were infected with lentiviral vectors containing either shRNA targeting IKBKE or TBK1. (B) Western blot analysis of pYB1, MYC, and ACTIN levels in MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1. (C) Western blot analysis of pYB1, pSerAKT, MYC, IKBKE, TBK1, and ACTIN levels in MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1. (D) Bar graph showing the relative protein levels of pYB1, MYC, and Total YB-1 in MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1. (E) Western blot analysis of MYC, pYB1, and Total YB-1 in MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1. (F) Bar graph showing the relative protein levels of MYC and Total YB-1 in MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1. (G) Western blot analysis of pYB1, Total YB-1, MYC, and ACTIN levels in MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1. (H) Bar graph showing the relative viability of MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1. (I) Western blot analysis of pYB1, Total YB-1, PARP cleavage, and Tubulin levels in MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1. (J) Western blot analysis of MYC, pYB1, and ACTIN levels in MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1. (K) Bar graph showing the relative protein levels of MYC and ACTIN in MOLM14 and OCIAML5 cells treated with momelotinib or shRNA-mediated knockdown of IKBKE or TBK1.
highest *IKBKE* expression is found in core-binding factor (t(8;21) and INV(16)) and t(15;17) AML (supplemental Figure 1B). These AML subtypes are generally associated with a favorable survival. Consistent with this, patients with the highest 10% *IKBKE* expression (probe 204549_at) showed a significantly better overall survival compared with other AML patients in a univariate model (supplemental Figure 1C).

We also evaluated the transcript level of the close homolog of *IKBKE*, TANK-binding kinase 1 (*TBK1*), and found there is no significant difference of expression between tumor types (supplemental Figure 2A). *TBK1* expression is higher in AML vs normal CD34+ cells (supplemental Figure 2B left), with the highest expression among AML patients found in *NPM1* mutated samples (supplemental Figure 2C). Compared with other genetically defined AML subtypes, *TBK1* expression was low in *IDH2*-mutated AML (supplemental Figure 2C). There was no difference in survival based on *TBK1* expression, nor was there a correlation between *TBK1* expression and *IKBKE* expression in individual samples (data not shown).

**AML cells depend on IKBKE/TBK1 for survival**

To determine the functional significance of this increased expression of *IKBKE*, we first used RNA interference to deplete IKBKE or *TBK1* in AML cells (Figure 2A). We found that most, but not all, AML cell lines show decreased viability in response to IKBKE/TBK1 depletion (Figure 2B). Consistent with this observation, significantly increased apoptosis was observed in AML cells that are sensitive to IKBKE/TBK1 knockdown, but not in cells that are resistant to knockdown (Figure 2C).

Next, we overexpressed IKBKE in AML cells and found that exogenous overexpression of IKBKE leads to an enhancement of viable cell number. This effect of IKBKE is dependent on its kinase activity, as a mutant form lacking kinase activity does not support this effect (Figure 2D). Given this finding, we then evaluated the effects of small molecular inhibitors of IKBKE/TBK1 on AML cell viability. Because a selective, clinically applicable IKBKE/TBK1 inhibitor is not available, we used momelotinib (CYT387), which inhibits JAK kinases as well as IKBKE/TBK1.20 As a comparison, we used ruxolitinib, which only inhibits JAK1 and JAK2 with no activity against IKBKE/TBK1.20 We first examined AML cell lines that require JAK/STAT signaling for proliferation, including OCI-AML5 and SKNO, which require culture in GM-CSF, and HEL, which contains a JAK2 V617F mutation. In these cells, both momelotinib and ruxolitinib inhibit viability with similar potency (supplemental Figure 3). By contrast, in AML cell lines in which JAK/STAT signaling is not required for survival, momelotinib potently inhibits AML cell viability, whereas ruxolitinib has no effect (Figure 2E). These findings suggest that the reduction of viability seen in these cell lines in response to momelotinib is likely due to IKBKE/TBK1 inhibition. There is a range of sensitivities of AML cells to momelotinib (Figure 2F), and this shows a strong correlation with sensitivity to shRNA mediated knockdown of IKBKE/TBK1 (supplemental Figure 4). It should also be noted that momelotinib inhibits TBK1 with a 50% inhibitory concentration in the high nanomolar range in in vitro assays.24 This matches the effective concentrations of momelotinib in the IKBKE-sensitive AML cells. In addition, concentrations in the range of 2 μM can be achieved in humans,25 so again, the concentrations used have the potential for clinical relevance.

**IKBKE/TBK1 modulates the MYC signaling pathway in AML cells**

We next focused on understanding the key molecular pathways downstream of IKBKE/TBK1 in AML. To do this, we used 2 complementary approaches. We first made use of the fact that AML cell lines could be segregated based on their sensitivity to IKBKE/TBK1 inhibition. We then used the Cancer Cell Line Encyclopedia (http://www.broadinstitute.org/ccle) to obtain the transcriptome profiles of each AML cell line analyzed and then performed GSEA comparing the IKBKE/TBK1 inhibition-sensitive (MOLM14, OCIAML5, HL60, and KASUMI-1) vs -insensitive (MV4-11, KG-1a, MONO-1, and AML193) lines. This analysis revealed a small number of gene sets that are particularly enriched in AML cells sensitive to IKBKE/TBK1 inhibition (Table 1). To further narrow down the gene sets and corresponding signaling pathways that are modulated by IKBKE, we then carried out gene expression profiling to determine global transcriptome changes upon IKBKE/TBK1 inhibition induced by momelotinib in 2 sensitive AML cell lines. We identified 241 genes that were upregulated and 312 genes that were downregulated in both MOLM14 and OCIAML5 cells after 6 hours of treatment with momelotinib.
Figure 5. Momelotinib inhibits MYC expression and reduces viability and colony formation of primary AML samples. (A) Bone marrow mononuclear cells harvested from 8 untreated patients with AML were treated with momelotinib (CYT) at the indicated concentrations for 72 hours, at which point relative viable cell number was determined by adenosine triphosphate–dependent bioluminescence. (B) Primary AML samples were treated with vehicle, momelotinib (CYT; 2.5 μM), or ruxolitinib (2.5 μM) for 6 hours, after which RNA was harvested for c-MYC quantitation by RT-PCR. (C) CFU-GEMM assays were performed on 4 primary AML samples and CD34+ bone marrow...
momeletinib (supplemental Tables 1 and 2). Next, we used the 312 downregulated genes as a gene set and computed overlap with Molecular Signature Database 6.1 through Gene Set Investigation. This method allowed us to identify pathways that are inhibited by momeletinib treatment (Table 2). In integrating these 2 analyses, it became clear that gene sets representing the MYC transcriptional program were specifically enriched in cell lines that are sensitive to IKBKE/TBK1 inhibition (Figure 3A) and that the MYC transcriptional program was inhibited by momeletinib. This raised the possibility that a key downstream target of IKBKE/TBK1 in AML cells is the MYC signaling pathway, and AML cells with an activated MYC transcriptional program are more likely to be sensitive to IKBKE/TBK1 inhibition.

To further validate these findings, we used 2 additional IKBKE/TBK1 inhibitors, MRT6730722 and BX795,26 to determine their effect on MYC expression. All 3 pharmacologic inhibitors of IKBKE/TBK1 decreased MYC messenger RNA (mRNA) and protein expression, whereas the Jak inhibitor ruxolitinib showed no effect on MYC expression (Figure 3B-C). Using an MYC mini-signature gene list,27 we also directly validated that the MYC transcriptional program was inhibited by momeletinib treatment (Figure 3D). This did not reflect a general inhibition of transcription, as a panel of NF-κB target genes was not inhibited by momeletinib (supplemental Figure 5). We also wished to evaluate the effect of these IKBKE/TBK1 inhibitors on MYC expression in cells that were resistant to IKBKE/TBK1 inhibition. In KG-1α and MV411 cells, both of which are resistant to IKBKE/TBK1 inhibition, none of the 3 drugs affected MYC levels (supplemental Figure 6). Furthermore, we evaluated a panel of MYC target genes in KG-1α cells, and these were also not significantly affected by treatment with these inhibitors. Taken together, these results show that the MYC pathway is inhibited by IKBKE/TBK1 inhibition only in AML cells sensitive to the cytotoxic effects of these drugs, and that MYC pathway inhibition correlates with the sensitivity of AML cells.

To further confirm that MYC inhibition by momeletinib is mediated through inhibition of IKBKE, we knocked down IKBKE or TBK1 in AML cells using RNA interference. We found reduced MYC mRNA and protein levels following knockdown of either IKBKE or TBK1 (Figure 3E-F), with concurrent reduction in the MYC transcriptional profile, as well (Figure 3G). These results demonstrate that inhibition of IKBKE/TBK1 downregulates the MYC oncogenic pathway in AML cell lines.

**IKBKE/TBK1 modulates MYC through phosphorylation of YB-1**

To understand the mechanism of MYC regulation by IKBKE/TBK1, we first considered effects on the NF-κB pathway, which is known to be regulated by these kinases. However, neither NF-κB nuclear translocation nor NF-κB–dependent luciferase reporter activity was inhibited by momeletinib (supplemental Figure 7). Furthermore, Gene Set Investigation of mRNA profiles from leukemia cell lines treated with momeletinib did not show evidence of NF-κB pathway inhibition (Table 2). Finally, expression of a panel of NF-κB target genes was not inhibited by momeletinib in sensitive AML cell lines (supplemental Figure 5). Thus, although NF-κB may be a key target of IKBKE/TBK1 inhibitors in solid tumors, it does not appear to be inhibited in AML cells.

In considering other mechanisms by which IKBKE/TBK1 could modulate MYC expression, we hypothesized that IKBKE/TBK1 phosphorylated other proteins that possess transcriptional or translational modulatory functions. To examine this possibility in an unbiased fashion, we carried out RPPA21 in MOLM14 and OCIAML5 cell lines treated with either momeletinib or shRNA knockdown of IKBKE/TBK1. With momeletinib treatment, we selected a short treatment duration of 2 and 6 hours in each cell line to focus on proteins that are more likely to be direct substrates of IKBKE/TBK1. As an internal control, we first verified that inhibition of IKBKE/TBK1 by either shRNA knockdown or pharmacologic inhibitors led to a decrease in MYC protein levels (supplemental Table 3). We then found significant and consistent reduction in the serine phosphorylated form of the oncogenic transcription/translation factor YB-1 upon IKBKE/TBK1 inhibition (Figure 4A). We validated this observation by showing that all 3 small molecule inhibitors of IKBKE/TBK1 reduced phosphorylation of YB1 (Ser102), without affecting total YB1 protein levels. Reduction of YB1 phosphorylation occurs in a dose-dependent manner and as early as 15 minutes following treatment with a pharmacologic inhibitor of IKBKE/TBK1 (Figure 4B). This rapid inhibition of YB-1 phosphorylation suggests that this could be a direct mediator of the effect of IKBKE/TBK1 on MYC expression.

We then considered whether IKBKE/TBK1 directly phosphorylates YB-1. To examine this possibility, we used Kinase-specific Phosphorylation Site Prediction software (GPS 3.0; http://gps.biocuckoo.org). Based on substrate sequence preference, it was predicted that IKBKE/TBK1 would not directly phosphorylate YB-1 on Ser102. This suggested that another kinase that is activated by IKBKE/TBK1 is directly phosphorylating YB-1. It has been shown that YB-1 can be directly phosphorylated by AKT28-30 in epithelial systems, and AKT is a substrate for IKBKE/TBK1. Therefore, we considered whether AKT is phosphorylating YB-1 in AML cells. We treated MOLM14 cells with the PI3 kinase inhibitor LY294002, to block the activating phosphorylation of AKT. We found that LY294002 completely inhibited AKT phosphorylation, but had almost no effect on YB-1 phosphorylation; by contrast, momeletinib completely abolished YB-1 phosphorylation whereas having minimal effects on AKT phosphorylation (Figure 4C). Furthermore, in OCIAML5 cells, all 3 IKBKE/TBK1 inhibitors reduced YB1 phosphorylation. However, no AKT phosphorylation could be detected in these cells, and YB1 phosphorylation was completely unaffected by LY294002 (Figure 4C). Thus, AKT does not appear to mediate the signal from IKBKE/TBK1 to phosphorylate YB-1 in AML cells.

We next investigated whether the effect of IKBKE/TBK1 on MYC expression is mediated through YB-1. First, we found that phosphorylation of YB-1 and expression of MYC decreased in a parallel, dose-dependent manner in MOLM14 cells treated with momeletinib (Figure 4D), making a direct effect plausible. We then

---

**Figure 5.** (continued) cells from 3 healthy donors, each performed in triplicate. Momeletinib treatment caused a dose-dependent decrease in colony formation in both AML samples and CD34+ controls, with a more pronounced effect on AML samples. Data are normalized to the DMSO-treated control, and the number of input cells. Statistically significant differences between AML and control samples treated with the same concentration of momeletinib are indicated. **P < .001, *P < .01.**
Figure 6. Momelotinib shows on-target therapeutic efficacy in a human AML xenograft model. (A) Tumor burden of NSG mice quantitated by whole-body bioluminescence imaging following IV injection of MOLM14-luc<sup>+</sup> cells. Mice were randomly assigned to receive momelotinib (CYT) 100 mg/kg orally daily, 10 mg/kg orally daily, or vehicle control. Data are presented as mean ± standard error of the mean (n = 8/group). ***P = .0004 by unpaired Student t test. (B) Representative whole-body bioluminescent images of mice orthotopically xenografted with MOLM14-luc<sup>+</sup> cells and treated with momelotinib (CYT; 100 mg/kg oral daily) or vehicle control. (C) Mice were...
examined the relationship between YB-1 phosphorylation and MYC protein expression in a panel of 9 AML cell lines upon momelotinib treatment. Again, there was a strong correlation between inhibition of YB-1 phosphorylation and reduction of MYC among these cell lines (Figure 4E). In addition, knocking down YB-1 reduced MYC mRNA and protein expression (Figure 4F-G) and significantly reduced viability through induction of apoptosis in AML cells (Figure 4H-I). To determine if YB-1 is the key intermediate between IKBKE/TBK1 and MYC expression, we made use of a constitutively active form of YB-1 in which serine-102 has been replaced with an aspartate residue (S102D).31 mimicking the negative charge of phosphorylation at this site. Expression of this construct rescued the inhibition of MYC expression induced by momelotinib treatment (Figure 4J) and largely rescued the induction of apoptosis mediated by this drug (Figure 4K). Taken together, these results indicate that IKBKE/TBK1 modulates MYC expression in AML cells through phosphorylation of YB-1.

Because YB-1 has been reported to act through both transcriptional and translational mechanisms, we next investigated how phosphorylated YB-1 modulates MYC expression. As noted, YB-1 inhibition by either momelotinib treatment or RNA interference leads to reduction of MYC mRNA levels, suggesting that YB-1 modulates MYC transcription. We further analyzed the dynamics of MYC mRNA levels in MOLM14 cells treated with momelotinib and compared it with cells treated with actinomycin D or the bromodomain inhibitor JQ1, both of which inhibit MYC transcription. We found that the rate of decay of MYC mRNA was identical in cells treated with momelotinib, actinomycin D, or JQ1 (supplemental Figure 8). Combined treatment with actinomycin D and momelotinib did not further accelerate the reduction of MYC mRNA levels, suggesting that MYC mRNA stability is unaffected by these treatments. These observations support the hypothesis that phosphorylation of YB-1 modulates MYC at the transcriptional level. Therefore, we determined whether YB-1 could directly bind to the MYC promoter, which contains a cytidine-thymidine–rich promoter element to which YB-1 can bind.32 We performed ChIP, which confirmed that YB-1 binds directly to this site (Figure 4L). Furthermore, this binding of YB-1 was lost when cells were pretreated with momelotinib. Taken together, these data provide evidence that YB-1 modulates MYC transcription.

Inhibition of IKBKE/TBK1 shows therapeutic benefit in vitro and in vivo models of AML

To determine whether these effects of IKBKE/TBK1 inhibition extended to primary AML cells, we next determined the effect of pharmacologic inhibitors on AML cells isolated from bone marrow aspirates. Interestingly, the AML samples segregated into 2 groups according to their sensitivity to momelotinib and ruxolitinib (Figure 5A). Three of the 8 AML samples demonstrated similar sensitivity to both momelotinib and ruxolitinib, suggesting that Jak activity may play a major role in cell viability in these samples. However, in the other 5 samples, only momelotinib reduced viability significantly, and the cells showed little response to ruxolitinib. We next examined the effect of these drugs on MYC mRNA expression. In the first group of patients, MYC was reduced by both momelotinib and ruxolitinib to similar extents, indicating that MYC expression is most likely modulated by Jak-mediated signaling in those samples (Figure 5B). In the second group, momelotinib decreased MYC expression to a much greater extent than ruxolitinib, suggesting that MYC is likely modulated largely by IKBKE/TBK1 in these samples. These observations suggest that IKBKE/TBK1 is an important driver of MYC expression in a significant fraction of primary AML cells.

To further understand the role of IKBKE/TBK1 on the biology of primary AML cells, we studied the effects of momelotinib on growth and self-renewal of AML cells and normal hematopoietic stem and progenitor cells by CFU assays. Momelotinib treatment caused a dose-dependent reduction in colony numbers in CFU assays in all AML samples (Figure 5C; supplemental Figure 9). A decrease in colony numbers was also seen in control CD34+ cells, particularly at high momelotinib concentrations, although this effect was less prominent than that seen in the leukemic cells. With replating, a similar decrease in colony number and cell number was seen with both AML cells and CD34+ cells from healthy subjects (supplemental Figure 9). Thus, although the anti–leukemic effect of momelotinib is apparent in these colony-forming assays, it is possible that inhibition of IKBKE/TBK1 could also have deleterious effects on normal CD34+ cells with prolonged use.

To assess the therapeutic effect of momelotinib in vivo, we evaluated its efficacy in an aggressive mouse model of human AML. MOLM14 cells engineered to express firefly luciferase were injected IV into NSG mice, after which disseminated leukemia was visualized and quantified by bioluminescence imaging. In this model, leukemic cells primarily populate the bone marrow, recapitulating the human disease. Mice were treated with vehicle or 1 of 2 doses of momelotinib (10 mg/kg or 100 mg/kg) administered by gavage for 28 days. Both regimens were well tolerated, and the weight and appearance of the mice remained stable in both treatment groups and controls. Although treatment with the 10-mg/kg dose showed a modest effect in reducing total disease burden, treatment at 100 mg/kg significantly decreased the tumor burden (Figure 6A-B). To determine the pharmacodynamic effects of momelotinib, mice were euthanized 2 hours after the last dose of treatment on day 28, and spleens were harvested. Momelotinib showed a dose-dependent decrease in spleen size in treated mice (Figure 6C). Furthermore, momelotinib showed a dose-dependent inhibition of total IKBKE (a surrogate for kinase inhibition), YB-1 phosphorylation, and MYC mRNA and protein (Figure 6D-F). Consistent with findings in other cancer models,7 prolonged treatment with momelotinib also reduced the total level of IKBKE as well (Figure 6G). These findings indicate that inhibition of IKBKE, and decreased YB-1 phosphorylation and MYC expression, correlates with decreased leukemia burden in an in vivo model of human AML.

Figure 6. (continued) euthanized 2 hours after the last treatment on day 28. Representative spleens from each treatment group are shown. (D) Protein extracts were made from spleens from each treatment group. Representative immunoblots from 2 spleens from each treatment group are shown. (E) Band intensity for immunoblots from all spleen samples were quantified by ImageJ. **P < .0059 by Welch t test. (F) mRNA was harvested from spleens from each treatment group, and c-MYC was quantitated by RT-PCR. *P < .0108 by Welch t test. (G) IKBKE expression (normalized to actin) was quantitated from the immunoblot in panel D using ImageJ.
Discussion

In this study, we have characterized a distinct IKBKE-dependent survival pathway in AML. Inhibition of IKBKE induces apoptosis and significantly reduces viability of a majority of AML cell lines and primary cells. Conversely, overexpressing IKBKE promotes leukemia cell survival. IKBKE knockout mice are viable, with only impaired initiation of a productive interferon-β response.33 Thus, although IKBKE may be essential for leukemia cell survival, it is dispensable for normal hematopoiesis, suggesting that IKBKE is a therapeutic target with a potentially high therapeutic index in AML.

Our efforts to understand the characteristics of AML cells that define sensitivity to IKBKE/TBK1 inhibition and to decipher the molecular pathways downstream of IKBKE/TBK1 both converged on the MYC transcriptional program. MYC inhibition appears essential in mediating the cytotoxicity of IKBKE inhibitors in AML cells, and AML cells that are dependent on the MYC transcriptional program are most likely sensitive to IKBKE/TBK1 inhibition. In AML cells lacking MYC expression, or in which MYC is not inhibited by momelotinib, there is little viability change upon momelotinib treatment. A small number of AML cell lines and primary AML samples showed no change in viability in response to momelotinib despite displaying a decrease in MYC expression. It is possible that in those cells, other survival pathways may be able to substitute in the setting of MYC inhibition, or those cells may not depend on MYC for survival.

In understanding the mechanism of MYC downregulation upon IKBKE inhibition, we identified phosphorylated YB-1 as a key intermediate. YB-1 is a central regulator of gene expression and is subject to post-translational modifications, such as phosphorylation, ubiquitination, and acetylation.34 Although the role of ubiquitination and acetylation in the functional activity of YB-1 is less understood, phosphorylation of YB-1 has been shown to promote its nuclear translocation and oncogenic activity.30 Although a functional relation between YB-1 and MYC expression has been suggested previously,31,35-37 the present study indicates that it is the phosphorylated form of YB-1 that is crucial in mediating MYC expression in AML. We observed a very high correlation between the inhibition of YB-1 phosphorylation by momelotinib and reduction in MYC expression. Importantly, a constitutively active form of YB-1 rescues MYC expression with momelotinib treatment. All of these observations support a central role for the phosphorylation of serine 102 of YB-1 in modulating MYC expression in AML cells.

As a DNA and RNA binding protein, YB-1 can bind DNA to regulate transcription or it can bind RNA to modulate its stability or translation. YB-1 has been suggested to modulate MYC transcription by binding to a promoter region of MYC,32,35 which leads to docking of core transcription factors and RNA polymerase II.34 On the other hand, YB-1 has also been shown to modulate MYC protein translation in multiple myeloma cells without influencing transcription.36,37 Our data show that either YB-1 knockdown or pharmacologic inhibition of YB-1 phosphorylation reduces MYC mRNA in parallel with MYC protein levels. Furthermore, the kinetics of the decrease in MYC mRNA induced by IKBKE inhibitors overlaps with the changes induced by compounds that inhibit MYC transcription, such as JQ1 and actinomycin D. Finally, ChIP analysis demonstrated that YB-1 binds directly to the MYC promoter, and this binding is disrupted upon inhibition of YB-1 phosphorylation by momelotinib treatment. Together, these observations support the notion that YB-1, particularly the serine-phosphorylated form, modulates MYC transcription in AML cells.

Bromodomain inhibitors, such as JQ1, have been shown to inhibit MYC expression in certain tumor systems and are being evaluated in clinical trials. However, by inhibiting transcription at so-called superenhancers, they may have much broader effects on non-malignant cells. Because YB-1–driven MYC expression may be a less common cellular mechanism, blocking this pathway specifically may hold the promise of having a higher therapeutic index for treating cancers commonly driven by this mechanism, such as AML. It is also possible that combinations of IKBKE/TBK1 and bromodomain inhibitors may have beneficial effects, including a decrease in the emergence of resistance. However, further studies will be needed to define the potential utility of this approach.

YB-1 clearly sits at a convergence point of a number of kinase pathways. For example, there is evidence that AKT28 can phosphorylate this protein. Nevertheless, our studies show that YB-1 is a key downstream target of IKBKE, independent of these other kinases, in a majority of AML cell lines. However, it remains to be determined whether IKBKE is phosphorylating this protein directly or is acting through an intermediary kinase. In conclusion, IKBKE/TBK1 modulates MYC through phosphorylation of YB-1 in a significant subset of AML cells. Importantly, it is the activation state of the IKBKE/YB-1/MYC pathway in AML cells, rather than IKBKE or TBK1 expression alone, that determines the sensitivity of AML cells to IKBKE/TBK1 inhibition. The dual JAK and IKBKE/TBK1 inhibitor momelotinib, which has shown a good safety profile in a clinical trial for myelofibrosis,38 may have therapeutic benefits in AML patients whose leukemia is dependent on IKBKE. In addition, the identification of phosphorylated YB-1 as a key downstream mediator leading to MYC expression provides a potential biomarker to select patients and predict and monitor therapeutic effects of IKBKE/TBK1 inhibitors in the treatment of AML.

Acknowledgments

The authors thank David Dorman and Susanna Stinson for helpful experimental advice.

This work was supported by National Institutes of Health (NIH), National Cancer Institute grant R01-CA160979, the Gabrielle’s Angel Foundation (New York, NY), and the Brent Leahey Fund (Dana-Farber Cancer Institute (D.A.F.)); NIH, National Heart, Lung, and Blood Institute training grant T32HL116324 (S.L.); EMBO fellowship ALTF 268-2017 (A.E.M.); and a Leukemia and Lymphoma Society Scholar Award, NIH, National Cancer Institute grant R35CA210030, and a St. Baldrick’s Foundation Robert J. Arcciei Innovation Award (K.S.). This research was also supported by a generous gift from Stephen P. Koster.

Authorship


Conflict-of-interest disclosure: D.B. is a consultant for N of One. D.A.F. has received research funding from Gilead Sciences. The remaining authors declare no competing financial interests.

Correspondence: David A. Frank, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215; e-mail: david_frank@dfci.harvard.edu.
References


